DE · AMG.DE
Amgen Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Thousand Oaks, CA 91320-1799
- Website
- amgen.com
Price · as of 2025-12-31
$296.80
Market cap 178.97B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $266.70 | -10.14% |
| Intrinsic Value(DCF) | $262.86 | -11.44% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $216.70 | -26.99% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $33.45 | $54.15 | $16.52 | $17.20 | $40.20 |
| 2012 | $46.65 | $61.15 | $21.91 | $12.50 | $88.40 |
| 2013 | $61.03 | $73.18 | $26.83 | $12.80 | $92.10 |
| 2014 | $109.40 | $101.79 | $36.28 | $10.10 | $88.30 |
| 2015 | $90.58 | $107.28 | $106.13 | $13.60 | $123.50 |
| 2016 | $115.42 | $127.18 | $139.35 | $10.00 | $124.00 |
| 2017 | $117.49 | $140.54 | $95.02 | $0.00 | $17.50 |
| 2018 | $132.56 | $154.87 | $71.75 | $0.00 | $129.70 |
| 2019 | $144.18 | $156.32 | $55.82 | $0.00 | $73.10 |
| 2020 | $172.37 | $167.99 | $15.26 | $0.00 | $175.30 |
| 2021 | $184.74 | $174.14 | $9.87 | $0.00 | $90.40 |
| 2022 | $193.98 | $195.28 | $0.43 | $0.00 | $98.50 |
| 2023 | $233.60 | $252.29 | $9.81 | $0.00 | $158.20 |
| 2024 | $277.78 | $260.28 | $17.96 | $0.00 | $168.70 |
| 2025 | $329.20 | $312.16 | $277.35 | $0.00 | $216.70 |
AI valuation
Our deep-learning model estimates Amgen Inc.'s (AMG.DE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $266.70
- Current price
- $296.80
- AI upside
- -10.14%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$262.86
-11.44% upside
Graham-Dodd
—
— upside
Graham Formula
$216.70
-26.99% upside
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- CEO
- Robert A. Bradway
- Employees
- 28K
- Beta
- 0.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($262.86 ÷ $296.80) − 1 = -11.44% (DCF, example).